Cookies?
Library Header Image
LSE Research Online LSE Library Services

Preventing cardiovascular events with empagliflozin: at what cost?

Naci, Huseyin, Basu, Sanjay and Yudkin, John S (2015) Preventing cardiovascular events with empagliflozin: at what cost? The Lancet Diabetes and Endocrinology, 3 (12). p. 931. ISSN 2213-8587

[img]
Preview
PDF - Accepted Version
Download (185kB) | Preview

Identification Number: 10.1016/S2213-8587(15)00439-8

Abstract

The EMPA-REG OUTCOME study,1 as the first randomised trial to show that a glucose-lowering intervention was associated with reduced cardiovascular events,2 raises important questions for policy makers. Chief among these questions is whether the detected effect size produces a cost-effective risk reduction from the studied pharmacological approach. The study has undoubtedly brought good news for the trial funders: analysts predict that its findings will propel empagliflozin ahead of other glucose-lowering drugs in sales.

Item Type: Article
Official URL: http://www.thelancet.com/
Additional Information: © 2015 Elsevier Ltd
Divisions: LSE Health
Subjects: R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Sets: Research centres and groups > LSE Health
Date Deposited: 26 Feb 2016 17:01
Last Modified: 20 Mar 2019 02:46
URI: http://eprints.lse.ac.uk/id/eprint/65545

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics